Absorption

Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update

Retrieved on: 
Wednesday, March 20, 2024
Joint venture, Patient, Sale, Business analyst, CCHN, IP, Marketing, Research, Mallinckrodt, Absorption, European Economic Area, Gross metropolitan product, Webcast, Asset, Alvogen, Denosumab, Neovascularization, Biosimilar, Macular degeneration, Safety, Food, U.S. FDA, Teva Pharmaceuticals, Revenue, Q3, CES, AMD, FDA, ISK, Administration, Adalimumab, Research and development, Pharmaceutical industry

Management will conduct a business update conference all and live webcast on March 21, 2024 at 8:00 am ET (12:00 pm GMT).

Key Points: 
  • Management will conduct a business update conference all and live webcast on March 21, 2024 at 8:00 am ET (12:00 pm GMT).
  • Alvotech announced positive top-line results from a pharmacokinetic (PK) study for AVT05, a biosimilar candidate to Simponi® and Simponi Aria® (golimumab).
  • Alvotech announced positive top-line results from a PK study for AVT03, a biosimilar candidate to Prolia® and Xgeva®, which both contain denosumab.
  • Alvotech will conduct a business update conference call and live webcast on Thursday, March 21, 2024, at 8:00 am ET (12:00 pm GMT).

ProPhase Labs Announces Financial Results for the Year Ended December 31, 2023 and Significant Progress in Its Strategic Initiatives

Retrieved on: 
Friday, March 15, 2024
Research, WGS, Automation, Genomics, Absorption, Health, Development, Growth, Exercise, Nebula Genomics, COVID-19, Patient, PMI, RNA, Sale, Acquisition, Public expenditure, Food, Engineering, Insurance, Protein, Diagnosis, RNA-Seq, Omicron, Prophase, HRSA, Whole genome sequencing, Marketing, FDA, Genetic counseling, Cryptocurrency

Garden City, NY, March 15, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next-generation biopharma, genomics, and diagnostics company, today reported its financial and operational results for the full-year ended December 31, 2023.

Key Points: 
  • With this significant repositioning completed, Nebula Genomics can now deliver low-cost, high-precision genomic diagnostics across North America and the global market.
  • This agreement presents the possibility for significant expansion of its global footprint and paves the way for prospective future revenue streams.
  • Research and development costs for the year ended December 31, 2023 and 2022 were $1.4 million and $0.7 million, respectively.
  • Diluted earnings per share for the years ended December 31, 2023 and 2022 were $(0.98) and $1.02, respectively.

Aquestive Therapeutics Announces Pivotal Study for Anaphylm™ (epinephrine) Sublingual Film Successfully Meets Primary and Secondary Endpoints and Provides Clinical Development Update Following FDA Meeting

Retrieved on: 
Thursday, March 14, 2024
Blood pressure, Sinai Hospital, Anaphylaxis, Absorption, Angioedema, Plasma, Type, PD, Patient, Heart rate, Adrenaline, NDA, Epinephrine autoinjector, Cmax, Trial of the century, Mouth, Therapy, Safety, Oral medicine, Allergy, Vomiting, Swelling, FDA, Study, Food, Pharmaceutical industry

“We are extremely pleased with the pivotal study results as well as our recent FDA interaction,” said Daniel Barber, President and Chief Executive Officer of Aquestive.

Key Points: 
  • “We are extremely pleased with the pivotal study results as well as our recent FDA interaction,” said Daniel Barber, President and Chief Executive Officer of Aquestive.
  • “We believe we have a clear understanding of the remaining clinical development steps necessary for a pre-NDA meeting with the FDA in the second half of the year.
  • These latest study results show that the sublingual administration of epinephrine provides rapid and sustained levels of epinephrine similar to approved treatments.
  • The FDA noted that substantial progress had been made in the Anaphylm clinical development program and did not outline any new clinical development requirements.

TerrAscend Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Thursday, March 14, 2024
Private placement, Administration, Absorption, Private, Growth, Sale, Acquisition, G&A, Toronto Stock Exchange, Q2, TSX, GAAP, Internal Revenue Code, Calendar, THC, CAD, Video game

TORONTO, March 14, 2024 (GLOBE NEWSWIRE) -- TerrAscend Corp. (“TerrAscend” or the “Company”) (TSX: TSND, OTCQX: TSNDF), a leading North American cannabis company, today reported its financial results for the fourth quarter and full year ended December 31, 2023. All amounts are expressed in U.S. dollars and are prepared under U.S. Generally Accepted Accounting Principles (GAAP), unless indicated otherwise.

Key Points: 
  • Net revenue for the fourth quarter of 2023 was $86.6 million as compared to $69.0 million for the fourth quarter of 2022, representing year-over-year growth of 25.5%.
  • Gross profit margin for the fourth quarter of 2023 was 48.2% as compared to 44.6% in the fourth quarter of 2022.
  • General & Administrative expenses (G&A) for the fourth quarter of 2023 were $27.7 million as compared to $34.5 million in the fourth quarter of 2022.
  • Net cash provided by operating activities was $9.4 million for the fourth quarter of 2023 compared to $7.3 million in the fourth quarter of 2022.

ARECOR AND TRx BIOSCIENCES ESTABLISH RESEARCH COLLABORATION TO DEVELOP ORAL GLP-1 WITH ENHANCED BIOAVAILABILITY

Retrieved on: 
Tuesday, March 12, 2024
Absorption, Obesity, Diabetes, Human, Patient, Gastrointestinal tract, AREC, Semaglutide, Drug development, TRX, AIM, Peptide, Vaccine

Oral delivery of this class of drug is extremely challenging owing to the proteolytic nature of the digestive system which significantly reduces bioavailability.

Key Points: 
  • Oral delivery of this class of drug is extremely challenging owing to the proteolytic nature of the digestive system which significantly reduces bioavailability.
  • Using TRx Biosciences’ LipiCore™ oral delivery technology alongside Arecor’s formulation platform, Arestat™, the companies intend to jointly develop an oral GLP-1 receptor agonist product with enhanced physicochemical properties that can achieve higher oral bioavailability and stability.
  • Alongside TRx Biosciences and its expertise in targeted oral drug delivery, we have an opportunity to develop an enhanced oral GLP-1 receptor agonist product.
  • Success with semaglutide may offer a path to multiple oral peptide products with enhanced absorption and efficacy.”
    The collaboration provides scope for expansion, following the initial oral GLP-1 receptor agonist programme, to develop further oral peptide products.

RPM Reports Record Fiscal 2024 Third-Quarter Results

Retrieved on: 
Thursday, April 4, 2024
Other Manufacturing, Commercial Building & Real Estate, Construction & Property, Chemicals, Plastics, Home Goods, Manufacturing, Building Systems, Retail, Residential Building & Real Estate, Consumer, Absorption, Consolidated, Webcast, Capital expenditure, DIY, RPM International, CPG, MAP, SPG, Investment, Rationalization, PCG, RPM, Music

During the first nine months of fiscal 2024:

Key Points: 
  • During the first nine months of fiscal 2024:
    Cash provided by operating activities was $941.1 million compared to $263.0 million in the prior-year period.
  • CPG sales to increase in the low- to mid-single-digit percentage range compared to prior-year record results.
  • The company expects the following in the full-year fiscal 2024:
    Consolidated sales to increase near the midpoint of the previous outlook, which was an increase in the low-single-digit percentage range compared to prior-year record results.
  • For those unable to listen to the live call, a replay will be available from April 4, 2024, until April 11, 2024.

Apartments.com Publishes Multifamily Rent Report for First Quarter of 2024

Retrieved on: 
Thursday, April 4, 2024
Residential Building & Real Estate, Construction & Property, REIT, Absorption, Growth, North Jersey, Weakness, CoStar Group, Risk, News, Security (finance), Housing, Multimedia, Acceleration

Today, Apartments.com – a CoStar Group online marketplace – released an in-depth report of multifamily rent trends for the first quarter of 2024.

Key Points: 
  • Today, Apartments.com – a CoStar Group online marketplace – released an in-depth report of multifamily rent trends for the first quarter of 2024.
  • View the full release here: https://www.businesswire.com/news/home/20240404033182/en/
    The U.S. multifamily market staged a strong rebound in demand during the first quarter of 2024, as 104,400 units were absorbed, the highest number since the third quarter of 2021.
  • The national average annual asking rent rose by 0.7% in March compared to 0.8% in the two prior months.
  • The multifamily market is projected to add only 495,000 units in 2024, a 20% pullback from the prior year.

United States Agricultural Surfactants Markets, 2018-2023 and 2028: Growing Emphasis on Sustainable Agriculture, Increased Adoption of Precision Agriculture Practices - ResearchAndMarkets.com

Retrieved on: 
Wednesday, April 3, 2024
Chemicals, Plastics, Agriculture, Natural Resources, Manufacturing, Pesticide, UV, Absorption, Farmer, Face, Growth, Research, Plant, Agrochemical, Soil, Insecticide, Herbicide, Weather

The agricultural surfactants market in the United States is a significant and dynamic sector within the agrochemical industry.

Key Points: 
  • The agricultural surfactants market in the United States is a significant and dynamic sector within the agrochemical industry.
  • The increasing adoption of precision agriculture and sustainable farming practices further propels the market growth.
  • One of the key drivers propelling the United States Agricultural Surfactants Market is the increased adoption of precision agriculture practices.
  • The growing emphasis on sustainable agriculture practices is driven by various factors and is playing a significant role in shaping the United States Agricultural Surfactants Market.

Melt Pharmaceuticals Closes $24 Million Series B Preferred Stock Financing

Retrieved on: 
Tuesday, April 2, 2024
Medical Supplies, Biotechnology, FDA, Health, Pharmaceutical, Optical, Health Technology, Medical Devices, Hospitals, Surgery, Clinical Trials, Catalent, Series, Absorption, Midazolam, Ketamine, Medication

Melt Pharmaceuticals, Inc. (“Melt”), a clinical‑stage pharmaceutical company developing novel approaches for procedural sedation, today announced the completion of its Series B Preferred Stock financing of approximately $24 million from new and existing investors at a pre‑money valuation that increased nearly 150% from the pre-money valuation for Melt’s Series A Preferred Stock financing in 2019.

Key Points: 
  • Melt Pharmaceuticals, Inc. (“Melt”), a clinical‑stage pharmaceutical company developing novel approaches for procedural sedation, today announced the completion of its Series B Preferred Stock financing of approximately $24 million from new and existing investors at a pre‑money valuation that increased nearly 150% from the pre-money valuation for Melt’s Series A Preferred Stock financing in 2019.
  • The capital raised will primarily support the further development of MELT-300, including the MELT-300 Phase 3 program.
  • “With this round of financing, we’ve obtained the funding to further the development of MELT-300, including conducting our recently commenced Phase 3 program.
  • Their shared belief in the vision of MELT-300 and their confidence in its potential to revolutionize short-duration procedural sedation is incredibly valuable to us.”
    Newbridge Securities Corporation acted as the exclusive placement agent for the Series B Preferred Stock Offering.

Danimer Scientific Announces Fourth Quarter and Full Year 2023 Results

Retrieved on: 
Thursday, March 28, 2024
Research, Other Energy, Sustainability, Recycling, Environmental Health, Energy, Environment, Green Technology, Packaging, Science, Chemicals, Plastics, Manufacturing, PLA, PHA, Absorption, Conference, Danimer Scientific, Webcast, Public expenditure, Senior, Bank statement, DNMR, Plastic, Video game

Danimer Scientific, Inc. (NYSE: DNMR) (“Danimer” or the “Company”), a leading next generation bioplastics company focused on the development and production of biodegradable materials, announced today financial results for its fourth quarter and full year, ended December 31, 2023.

Key Points: 
  • Danimer Scientific, Inc. (NYSE: DNMR) (“Danimer” or the “Company”), a leading next generation bioplastics company focused on the development and production of biodegradable materials, announced today financial results for its fourth quarter and full year, ended December 31, 2023.
  • Our recently completed equity offering transaction enhances our operational liquidity runway and should enable us to support this expected growth.”
    Fourth Quarter 2023 Financial Highlights:
    Revenues were $10.9 million in the fourth quarter of 2023 compared to revenue of $15.3 million in the fourth quarter of 2022.
  • Adjusted EBITDA was $(10.7) million in the fourth quarter of 2023 compared to $(8.6) million in the fourth quarter of 2022.
  • Upon dialing in, please request to join the Danimer Scientific Fourth Quarter 2023 Earnings Conference Call.